Perhaps big pharma will be cautious until at least phase 1 is complete and no-one has died or had severe side effects. After all this is a totally new antibiotic with totally new mode of action.
Having said that, some degree of side effect (if not permanently damaging) ought to be acceptable where the alternative is death or disability from an otherwise untreatable superbug.
Ann: US FDA Grants Qualified Infectious Disease Product Designati, page-11
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $118.1M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 46.5¢ | 46.5¢ | $2.131K | 4.582K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1263 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 11173 | 5 |
View Market Depth
| Last trade - 12.38pm 04/12/2024 (20 minute delay) ? |
| RCE (ASX) Chart |
